New research has revealed that people taking weight loss drugs like Wegovy and Mounjaro are increasingly more likely to ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Ozempic, a type 2 diabetes treatment, presents investment opportunities via Novo Nordisk stock. Projected GLP-1 market growth to almost $160 billion by early the 2030s indicates long-term sector ...

Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs In a statement Monday, Novo Nordisk defended its pricing structure.

Novo Nordisk, the Danish company behind Ozempic and Wegovy, made one very dumb decision a few years ago that's now poised to massively eat into its profits — a wild twist in the pharma company's ...

Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.